Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by sponsor or company

Search by sponsors

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “AstraZeneca”

Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract CancerRecruiting
NCT06467357Phase 3Updated Aug 19, 2026
Sponsor: AstraZeneca
Biliary Tract Cancer
United States, Australia, Austria, Belgium, Brazil +22 more
Anifrolumab Pregnancy StudyRecruiting
NCT07049653N/AUpdated Aug 19, 2026
Sponsor: AstraZeneca
Systemic Lupus Erythematosus
United States
Chronic Kidney Disease Registry Platform StudyActive Not Recruiting
NCT06117852N/AUpdated Aug 19, 2026
Sponsor: AstraZeneca
Chronic Kidney Diseases
China
Study to Investigate Efficacy, Safety, and Tolerability of Zibotentan/Dapagliflozin Compared to Dapagliflozin in Participants With Chronic Kidney Disease and High Proteinuria (ZENITH High Proteinuria)Active Not Recruiting
NCT06087835Phase 3Updated Aug 19, 2026
Sponsor: AstraZeneca
Chronic Kidney Disease With High Proteinuria
United States, Argentina, Australia, Austria, Brazil +25 more
Non-interventional Study of Patients With Transthyretin (ATTR) AmyloidosisRecruiting
NCT06465810N/AUpdated Aug 19, 2026
Sponsor: AstraZeneca
Transthyretin Amyloidosis · ATTR-CM · ATTRv-PN · ATTR
United States, Canada, China, Germany, Spain +1 more
To Evaluate the Efficacy/Safety of Osimertinib Prior to CRT and Maintenance of it With Stage III, Unresectable NSCLC With EGFR MutationsActive Not Recruiting
NCT06194448Phase 2Updated Aug 19, 2026
Sponsor: AstraZeneca
Lung Cancer
United States, China, Israel, South Korea, Spain +4 more
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid TumorsRecruiting
NCT07115043Phase 1, Phase 2Updated Aug 19, 2026
Sponsor: AstraZeneca
Melanoma · Non-small Cell Lung Cancer · Squamous Cell Carcinoma (Skin) · Renal Cell Carcinoma
United States, Australia, Japan, South Korea
A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma PatientsRecruiting
NCT06549595Phase 3Updated Aug 19, 2026
Sponsor: AstraZeneca
Untreated Follicular Lymphoma
United States, Australia, Belgium, Brazil, Canada +18 more
AZD0486 as Monotherapy in B-cell Acute Lymphoblastic LeukaemiaRecruiting
NCT06137118Phase 1, Phase 2Updated Aug 19, 2026
Sponsor: AstraZeneca
B-cell Acute Lymphoblastic Leukemia (B-ALL)
United States, Australia, Brazil, Canada, China +8 more
A Study of AZD0292 in Chinese Participants With Bronchiectasis and Chronic Pseudomonas Aeruginosa ColonizationRecruiting
NCT07774403Phase 2Updated Aug 19, 2026
Sponsor: AstraZeneca
Bronchiectasis With Pseudomonas Aeruginosa Colonization
China
Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid MalignanciesActive Not Recruiting
NCT04644068Phase 1, Phase 2Updated Aug 19, 2026
Sponsor: AstraZeneca
Ovarian Cancer · Breast Cancer · Pancreatic Cancer · Prostate Cancer
United States, Australia, Canada, China, Czechia +9 more
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine TherapyRecruiting
NCT05774951Phase 3Updated Aug 19, 2026
Sponsor: AstraZeneca
Breast Cancer, Early Breast Cancer
United States, Argentina, Australia, Austria, Belgium +34 more
Safety, Pharmacokinetics and Clinical Activity of AZD0171 in Combination With Durvalumab and Chemotherapy in Locally Advanced or Metastatic Solid TumoursActive Not Recruiting
NCT04999969Phase 2Updated Aug 19, 2026
Sponsor: AstraZeneca
Locally Advanced or Metastatic Solid Tumours
United States, Canada, South Korea, Spain
Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic AlterationsActive Not Recruiting
NCT05215340Phase 3Updated Aug 19, 2026
Sponsor: Daiichi Sankyo
Metastatic Non Small Cell Lung Cancer
United States, Argentina, Australia, Austria, Belgium +23 more
Roll-over Study for Participants Who Have Completed a Previous Clinical Study With Benralizumab (Fasenra) and Benefit From Continued TreatmentRecruiting
NCT07444567Phase 3Updated Aug 19, 2026
Sponsor: AstraZeneca
Asthma · Eosinophilic Granulomatosis With Polyangiitis (EGPA) · Hypereosinophilic Syndrome (HES)
United States, Argentina, Austria, Belgium, Canada +9 more
A Phase I/II Study to Evaluate AZD5851 in GPC3+ Advanced/Recurrent Hepatocellular CarcinomaActive Not Recruiting
NCT06084884Phase 1, Phase 2Updated Aug 19, 2026
Sponsor: AstraZeneca
Hepatocellular Carcinoma
United States, Japan, South Korea
AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple MyelomaRecruiting
NCT06106945Phase 1, Phase 2Updated Aug 19, 2026
Sponsor: AstraZeneca
Multiple Myeloma
United States, Australia, Brazil, Canada, China +4 more
A Study to Evaluate the Efficacy, Safety, and PK of AZD0292 Administered IV in Participants 12 Years of Age and Older With Bronchiectasis and Chronic Pseudomonas Aeruginosa ColonizationRecruiting
NCT07088926Phase 2Updated Aug 18, 2026
Sponsor: AstraZeneca
Bronchiectasis With Pseudomonas Aeruginosa Colonization
United States, Argentina, Australia, Belgium, Brazil +20 more
Osimertinib With Chemotherapy as First-line Therapy for EGFR Mutation-positive NSCLCActive Not Recruiting
NCT06376084N/AUpdated Aug 18, 2026
Sponsor: AstraZeneca
Carcinoma, Non-Small-Cell Lung · Lung Neoplasms · Respiratory Tract Neoplasms · Thoracic Neoplasms
China
Ravulizumab Outcomes in Polish Patients With aHUSRecruiting
NCT07399730N/AUpdated Aug 18, 2026
Sponsor: AstraZeneca
Atypical Hemolytic Uremic Syndrome
Poland
Prospective Registry Investigating Maternal, Infant, and Lactation Outcomes in Anifrolumab UsersRecruiting
NCT06594068Phase 4Updated Aug 18, 2026
Sponsor: AstraZeneca
Systemic Lupus Erythematosus
United States
Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate CancerActive Not Recruiting
NCT03732820Phase 3Updated Aug 18, 2026
Sponsor: AstraZeneca
Metastatic Castration-resistant Prostate Cancer
United States, Australia, Belgium, Brazil, Canada +12 more
Aggressive Disease Treatment Patterns and CtDNA HRR evaluatiON in High-volume metastatiC hORmone-sensitive Prostate Cancer in Russian FeDerationRecruiting
NCT07052578N/AUpdated Aug 18, 2026
Sponsor: AstraZeneca
Prostate Cancer
Russia
A Single Arm, Phase 2 Study of Datopotamab Deruxtecan, Carboplatin, and Pembrolizumab for Treatment-naive Brain Metastases From NSCLC (Non-small Cell Lung Cancer)Recruiting
NCT06822543Phase 2Updated Aug 18, 2026
Sponsor: Latin American Cooperative Oncology Group
Lung Cancer · Non Small Cell Lung Cancer · Brain Metastases
Brazil
A Translational Study to Describe Clinical Characteristics, Biomarkers and to Identify Phenotypes and Endotypes Associated With Differential Outcomes in Chinese PopulationRecruiting
NCT06419413N/AUpdated Aug 18, 2026
Sponsor: AstraZeneca
Asthma
China

Previous page Next page